ARS Announces Acceptance of Market Authorization Application submission to European Medicines Agency for Neffy (ARS-1; epinephrine nasal spray)

SAN DIEGO, November 23, 2020 – ARS Pharmaceuticals (ARS) announced today that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application (MAA) submission for review of NeffyTM (ARS-1; epinephrine nasal spray) an epinephrine nasal spray for the emergency treatment of severe allergic reactions, including anaphylaxis. This follows ARS’...

ARS Pharmaceuticals and Recordati Announce Exclusive License for the Rights in Europe and additional countries for NeffyTM (ARS-1; epinephrine nasal spray)

Agreement will give access to millions at risk for severe allergic reaction to new pain-free delivery method for epinephrine and will help in efforts to gain regulatory approval for ARS-1 (known as NeffyTM in the U.S.) around the world SAN DIEGO SEPTEMBER 22, 2020—ARS Pharmaceuticals (ARS) announced that it has...

ARS Pharmaceuticals to Present New Data from Neffy™ (ARS-1) Studies at AAAAI 2020 Annual Meeting

First presentation of findings from EPI03, EPI04 and EPI07 studies that examine the pharmacokinetics and pharmacodynamics of single and repeat administration of epinephrine after intranasal, intramuscular and subcutaneous administration Additional analyses measure the effects of active seasonal allergic rhinitis symptoms on the absorption of intranasal epinephrine administered as Neffy™, and...

ARS Pharmaceuticals Announces Results from EPI-04 Clinical Study of ARS-1 Intranasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis

Results demonstrate rapid epinephrine absorption with an overall pharmacokinetic profile comparable to epinephrine injection in allergy-induced patients SAN DIEGO--(BUSINESS WIRE)--ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, today announced results from its EPI-04...